Morgan Stanley Arrowhead Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,605,766 shares of ARWR stock, worth $31.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,605,766

Previous 1,815,278 11.54%

Holding current value

$31.5 Million

Previous $47.2 Million 34.11%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $4.06 Million - $6.19 Million	-209,512 Reduced 11.54%	1,605,766 $31.1 Million
Q2 2024 Oct 17, 2024	BUY	$21.87 - $28.24 $14.9 Million - $19.2 Million	679,411 Added 59.81%	1,815,278 $47.2 Million
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $14.9 Million - $19.2 Million	679,411 Added 59.81%	1,815,278 $47.2 Million
Q1 2024 Oct 17, 2024	SELL	$27.21 - $39.48 $18.5 Million - $26.8 Million	-679,411 Reduced 37.43%	1,135,867 $32.5 Million
Q1 2024 Aug 16, 2024	BUY	$27.21 - $39.48 $6.43 Million - $9.33 Million	236,415 Added 26.28%	1,135,867 $32.5 Million
Q1 2024 May 15, 2024	BUY	$27.21 - $39.48 $6.43 Million - $9.33 Million	236,415 Added 26.28%	1,135,867 $32.5 Million
Q4 2023 Aug 16, 2024	SELL	$21.2 - $31.03 $19.4 Million - $28.4 Million	-915,826 Reduced 50.45%	899,452 $27.5 Million
Q4 2023 Feb 13, 2024	BUY	$21.2 - $31.03 $3.48 Million - $5.09 Million	164,026 Added 22.3%	899,452 $27.5 Million
Q3 2023 Nov 15, 2023	BUY	$26.2 - $36.08 $5.08 Million - $6.99 Million	193,812 Added 35.78%	735,426 $19.8 Million
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $2.33 Million - $3.83 Million	-92,654 Reduced 14.61%	541,614 $19.3 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $4.81 Million - $7.82 Million	203,081 Added 47.1%	634,268 $16.1 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $106,232 - $153,884	3,794 Added 0.89%	431,187 $17.5 Million
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $3.31 Million - $5.39 Million	-111,578 Reduced 20.7%	427,393 $14.1 Million
Q2 2022 Oct 27, 2022	BUY	$27.79 - $50.61 $6.53 Million - $11.9 Million	234,931 Added 77.27%	538,971 $19 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $6.53 Million - $11.9 Million	234,931 Added 77.27%	538,971 $19 Million
Q1 2022 Oct 27, 2022	SELL	$39.62 - $69.97 $9.31 Million - $16.4 Million	-234,931 Reduced 43.59%	304,040 $14 Million
Q1 2022 May 13, 2022	SELL	$39.62 - $69.97 $943,946 - $1.67 Million	-23,825 Reduced 7.27%	304,040 $14 Million
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $2.58 Million - $3.67 Million	44,499 Added 15.7%	327,865 $21.7 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $16.5 Million - $24.1 Million	283,366 New	283,366 $17.7 Million

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account